ReviewMedical oncology (Northwood, London, England)2025
ADAR1-mediated RNA editing in breast cancer: molecular mechanisms and therapeutic implications.
Review in Medical oncology (Northwood, London, England), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Targeting ADAR1 Restores Interferon Signaling and Enhances Immunotherapy Response in Multiple Myeloma.International journal of molecular sciences · 2026Article
- 8-Chloro-adenosine inhibits breast cancer progression by inducing ferroptosis via the ADAR1/miR-101-3p/SLC7A11 axis.Cancer cell international · 2026Article
- More than alternative estrogen receptors: the emerging role of GPER-1 and ERα36 in breast cancer.Exploration of targeted anti-tumor therapy · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
Breast cancer (BC) continues to be among the most widespread and clinically demanding cancers globally, resulting in significant illness and death, even with progress in early detection and treatment approaches. Traditional therapeutic modalities, including surgery, chemotherapy, and targeted therapies, often fail in the face of drug resistance, metastasis, and the invasion. Consequently, a pressing demand exists for new biomarkers and treatment approaches to enhance clinical results. A recent area of focus in cancer research is RNA editing, particularly the role of Adenosine deaminase acting on RNA1 (ADAR1) which operates as an RNA editing enzyme that catalyzes adenosine-to-inosine conversion within double-stranded RNA substrates. This process affects gene expression and various cellular functions including RNA stability, splicing, and translation. Recent studies have highlighted the important function of ADAR1 editing in several types of cancer, including breast cancer, by regulating key pathways that are critical to tumor development, proliferation, and therapeutic resistance. This review aims to inspire further research into ADAR1-mediated mechanisms, offering new perspectives to overcome therapeutic resistance and improve clinical outcomes. This review systematically examines the multifaceted roles of ADAR1 in breast cancer progression, with a focus on its upstream regulators and downstream effects on critical pathways. Our analysis not only consolidates current understanding of ADAR1's regulatory networks, but also pointed out the current problems with ADAR1 in breast cancer research. What's more, we also proposed innovative strategies such as ADAR1 inhibitors to advance precision medicine in breast cancer.
Indexed as
Identifiers
40782195What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.